Cellectar Biosciences announced that the European Medicines Agency has granted Priority Medicines designation to iopofosine I 131, the company’s lead small-molecule drug candidate, for Waldenstrom’s macroglobulinemia in patients who have received two or more prior treatment regimens.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CLRB:
- Cellectar Biosciences Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom’s Macroglobulinemia
- Cellectar Biosciences Announces Closing of up to Approximately $103 Million Private Placement Financing
- Biotech Alert: Searches spiking for these stocks today
- Cellectar Biosciences Announces up to Approximately $103 Million Private Placement Financing
- Cellectar Biosciences announces up to $103M private placement financing